FINWIRES · TerminalLIVE
FINWIRES

$NRIX

3 stories mentioning NRIXUpdated 6m ago

Every FINWIRES story that references NRIX, newest first.

Insider Trading

Nurix Therapeutics Insider Sold Shares Worth $382,358, According to a Recent SEC Filing

Christine Ring, Chief Legal Officer, on August 03, 2026, sold 16,589 shares in Nurix Therapeutics (NRIX) for $382,358. Following the Form 4 filing with the SEC, Ring has control over a total of 9,110 common shares of the company, with 9,110 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1549595/000181719926000028/xslF345X05/wk-form4_1785793916.xml

$NRIX
Wire

UBS Lifts Nurix Therapeutics Price Target to $31 From $23, Maintains Buy Rating

Nurix Therapeutics (NRIX) has an average rating of buy and mean price target of $32.50, according to analysts polled by FactSet.Price: $23.67, Change: $+0.19, Percent Change: +0.81%

$NRIX
Research

Wells Fargo Downgrades Nurix Therapeutics to Equal Weight From Overweight, Adjusts Price Target to $25 From $28

Wells Fargo Downgrades Nurix Therapeutics to Equal Weight From Overweight, Adjusts Price Target to $25 From $28

$NRIX

Track with the FINWIRES app suite

FolioX
FolioX
Track NRIX in your portfolio
WheelAI
WheelAI
Analyze NRIX options with the wheel strategy
StockInsider
StockInsider
See market sentiment on NRIX